Gender differences in cannabis use disorder symptoms: A network analysis.

Male Humans Female Marijuana Abuse / psychology Sex Factors Cannabis Anxiety Disorders / drug therapy Substance Withdrawal Syndrome / drug therapy Hallucinogens / therapeutic use
Addiction Cannabis Comorbidity Gender Network analysis Sex

Journal

Drug and alcohol dependence
ISSN: 1879-0046
Titre abrégé: Drug Alcohol Depend
Pays: Ireland
ID NLM: 7513587

Informations de publication

Date de publication:
01 02 2023
Historique:
received: 27 06 2022
revised: 17 11 2022
accepted: 01 12 2022
pubmed: 25 12 2022
medline: 21 1 2023
entrez: 24 12 2022
Statut: ppublish

Résumé

While cannabis use in women is increasing worldwide, research into gender differences in cannabis use disorder (CUD) symptomology is lacking. In response to limited effectiveness of addiction treatment, research focus has been shifting from clinical diagnoses towards interactions between symptoms, as patterns of symptoms and their interactions could be crucial in understanding etiological mechanisms in addiction. The aim of this study was to evaluate the CUD symptom network and assess whether there are gender differences therein. A total of 1257 Dutch individuals reporting weekly cannabis use, including 745 men and 512 women, completed online questionnaires assessing DSM-5 CUD symptoms and additional items on plans to quit or reduce use, cigarette use, and the presence of psychological diagnoses. Gender differences were assessed for all variables and an Ising model estimation method was used to estimate CUD symptom networks in men and women using network comparison tests to assess differences. There were gender differences in the prevalence of 6 of the 11 symptoms, but symptom networks did not differ between men and women. Cigarette use appeared to only be connected to the network through withdrawal, indicating a potential role of cigarette smoking in enhancing cannabis withdrawal symptoms. Furthermore, there were gender differences in the network associations of mood and anxiety disorders with CUD symptoms. The association between smoking and withdrawal as well as gender differences in the role of comorbidities in the CUD network highlight the value of using network models to understand CUD and how symptom interactions might affect treatment.

Sections du résumé

BACKGROUND
While cannabis use in women is increasing worldwide, research into gender differences in cannabis use disorder (CUD) symptomology is lacking. In response to limited effectiveness of addiction treatment, research focus has been shifting from clinical diagnoses towards interactions between symptoms, as patterns of symptoms and their interactions could be crucial in understanding etiological mechanisms in addiction. The aim of this study was to evaluate the CUD symptom network and assess whether there are gender differences therein.
METHODS
A total of 1257 Dutch individuals reporting weekly cannabis use, including 745 men and 512 women, completed online questionnaires assessing DSM-5 CUD symptoms and additional items on plans to quit or reduce use, cigarette use, and the presence of psychological diagnoses. Gender differences were assessed for all variables and an Ising model estimation method was used to estimate CUD symptom networks in men and women using network comparison tests to assess differences.
RESULTS
There were gender differences in the prevalence of 6 of the 11 symptoms, but symptom networks did not differ between men and women. Cigarette use appeared to only be connected to the network through withdrawal, indicating a potential role of cigarette smoking in enhancing cannabis withdrawal symptoms. Furthermore, there were gender differences in the network associations of mood and anxiety disorders with CUD symptoms.
CONCLUSION
The association between smoking and withdrawal as well as gender differences in the role of comorbidities in the CUD network highlight the value of using network models to understand CUD and how symptom interactions might affect treatment.

Identifiants

DOI: 10.1016/j.drugalcdep.2022.109733 PMID: 36565568
pubmed: 36565568
pii: S0376-8716(22)00470-7
doi: 10.1016/j.drugalcdep.2022.109733
pii:
doi:

Substances chimiques

Hallucinogens 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

109733

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest No conflict declared.

Auteurs

Emese Kroon (E)

Neuroscience of Addiction (NofA) Lab, Department of Psychology, University of Amsterdam, the Netherlands; ADAPT-laboratory, Department of Psychology, University of Amsterdam, the Netherlands. Electronic address: e.kroon@uva.nl.

Alessandra Mansueto (A)

ADAPT-laboratory, Department of Psychology, University of Amsterdam, the Netherlands; Centre for Urban Mental Health, University of Amsterdam, Amsterdam, the Netherlands; Psychological Methods, Department of Psychology, University of Amsterdam, the Netherlands; Amsterdam School of Communication Research (ASCoR), University of Amsterdam, Amsterdam, the Netherlands.

Lauren Kuhns (L)

Neuroscience of Addiction (NofA) Lab, Department of Psychology, University of Amsterdam, the Netherlands; ADAPT-laboratory, Department of Psychology, University of Amsterdam, the Netherlands.

Francesca Filbey (F)

School of Behavioral and Brain Sciences, University of Texas at Dallas, Dallas, TX, USA.

Reinout Wiers (R)

ADAPT-laboratory, Department of Psychology, University of Amsterdam, the Netherlands; Centre for Urban Mental Health, University of Amsterdam, Amsterdam, the Netherlands.

Janna Cousijn (J)

Neuroscience of Addiction (NofA) Lab, Department of Psychology, University of Amsterdam, the Netherlands; Department of Psychology, Education & Child Studies, Erasmus University Rotterdam, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Gender differences in cannabis use disorder...
questionsmedicales.fr › Troubles mentaux › Troubles liés à une substance › Abus de marijuana › Gender differences in cannabis use disorder...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Facteurs épidémiologiques › Facteurs sexuels › Gender differences in cannabis use disorder...
questionsmedicales.fr › Eucaryotes › Viridiplantae › Streptophyta › Embryophyta › Tracheobionta › Magnoliopsida › Rosanae › Rosales › Cannabaceae › Cannabis › Gender differences in cannabis use disorder...
questionsmedicales.fr › Troubles mentaux › Troubles anxieux › Gender differences in cannabis use disorder...
questionsmedicales.fr › Troubles mentaux › Troubles liés à une substance › Syndrome de sevrage › Gender differences in cannabis use disorder...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents du système nerveux central › Psychoanaleptiques › Hallucinogènes › Gender differences in cannabis use disorder...